Streetbeat News

Earnings

FORA

Forian (NASDAQ:FORA) reported Q2 earnings per share (EPS) of $(0.08), missing the analyst estimate of $(0.02) by 300%. Sales were $4.78M, missing the $5.26M estimate by 9.18%. This represents a 166.67% increase in losses and a 2.37% decrease in sales compared to the same period last year.

Portfolio Pulse from totan@benzinga.com

August 14, 2024 | 8:12 pm

SNAX

Stryve Foods has projected its FY24 net sales to be between $23 million and $26 million, compared to the estimated $25.675 million.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:12 pm

TECX

Tectonic Therapeutic (NASDAQ:TECX) reported a Q2 EPS loss of $(4.34), significantly missing the analyst consensus estimate of $(1.50) by 189.33%. This represents a 49% improvement over the $(8.51) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:11 pm

RSLS

Reshape Lifesciences (NASDAQ:RSLS) reported Q2 EPS of $(0.06), a significant improvement from $(1.08) YoY, but missed sales estimates with $1.97M, down 12.82% YoY.

Portfolio Pulse from saritha@benzinga.com

August 14, 2024 | 8:11 pm

STNE

StoneCo reported Q2 2024 revenue of R$3.205 billion.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:11 pm

SNAX

Stryve Foods (NASDAQ:SNAX) reported Q2 2024 adjusted EPS of $(0.83), beating the analyst estimate of $(1.39) by 40.29%. The company also reported sales of $6.20 million, surpassing the $5.01 million estimate by 23.80%. This represents a 3.39% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:11 pm

BEAT

HeartBeam (NASDAQ:BEAT) reported a Q2 2024 GAAP EPS of $(0.19), missing the analyst consensus estimate of $(0.17) by 11.76%. This represents an 18.75% increase in losses compared to $(0.16) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:10 pm

KOD

Kodiak Sciences (NASDAQ:KOD) reported a Q2 EPS of $(0.86), beating the analyst consensus estimate of $(1.19) by 27.73%. This represents a 43.79% improvement over the $(1.53) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:10 pm

PGEN

Precigen (NASDAQ:PGEN) reported Q2 2024 GAAP EPS of $(0.23), missing the $(0.10) estimate by 130%. Sales were $717K, missing the $1.28M estimate by 43.98%. This represents a 187.5% decrease in EPS and a 59.42% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:10 pm

SSKN

Strata Skin Sciences (NASDAQ:SSKN) reported Q2 sales of $8.40 million, surpassing the analyst consensus estimate of $7.42 million by 13.15%. This marks a 1.82% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:10 pm